Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gemcitabine in advanced bladder cancer].

J Lehmann1, M Retz, C Lippert

  • 1Klinik für Urologie und Kinderurologie, Universität des Saarlandes, Homburg/Saar. jan.lehmann@uniklinik-saarland.de

Der Urologe. Ausg. A
|February 8, 2003
PubMed
Summary

Gemcitabine plus cisplatin offers comparable outcomes to MVAC for advanced urothelial cancer but with better tolerability. A modified 3-week schedule further enhances patient comfort without sacrificing efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

GW170817: Implications for the Stochastic Gravitational-Wave Background from Compact Binary Coalescences.

Physical review letters·2018
Same author

First Search for Nontensorial Gravitational Waves from Known Pulsars.

Physical review letters·2018
Same author

Huddle test measurement of a near Johnson noise limited geophone.

The Review of scientific instruments·2017
Same author

GW170817: Observation of Gravitational Waves from a Binary Neutron Star Inspiral.

Physical review letters·2017
Same author

GW170814: A Three-Detector Observation of Gravitational Waves from a Binary Black Hole Coalescence.

Physical review letters·2017

Area of Science:

  • Oncology
  • Medical Chemotherapy
  • Urothelial Carcinomas

Context:

  • Methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) has been the standard treatment for advanced urothelial cancer for over 15 years.
  • Recent studies compare gemcitabine/cisplatin combination therapy to MVAC, evaluating response rates, survival, and toxicity.

Purpose:

  • To assess the effectiveness and tolerability of gemcitabine-based chemotherapy regimens in advanced urothelial cancer.
  • To compare gemcitabine/cisplatin combination therapy with the established MVAC regimen.

Summary:

  • Single-agent gemcitabine shows response rates of 11-28% in advanced urothelial cancers.
  • Gemcitabine/cisplatin combination therapy achieves response rates up to 50% with median survival of 12-15 months.
  • Triplet gemcitabine regimens can yield response rates up to 80%, especially in sequential therapy.

Related Experiment Videos

  • A German phase II study demonstrated improved tolerability by reducing the gemcitabine/cisplatin schedule from 4 to 3 weeks (gemcitabine on days 1 and 8).

    • Impact:

    • Gemcitabine/cisplatin provides a viable alternative to MVAC with a more tolerable toxicity profile for advanced urothelial cancer.
    • Optimized dosing schedules, such as the 3-week regimen, can enhance treatment tolerability without compromising efficacy.
    • These findings support the use of gemcitabine-based chemotherapy as a standard or alternative treatment option for advanced urothelial cancer.